This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology of ANCA associated vasculitis

Authoring team

  • annual incidence of ANCA-associated vasculitis (AAV) in Norfolk during 1988-2010 was estimated to be 19.5/million (GPA (Wegener) 11.3/million, MPA (microscopic polyangiitis) 5.9/million) with a prevalence of 255/million (1)
    • AAV entities are rare diseases with combined prevalence estimated at between 90 and 144 per million, and with annual incidence of around 20 per million (2)
  • peak age at diagnosis was 65-74 years, with a male preponderance
    • high age at onset has been confirmed from other centres in Europe (Spain and Scandinavia)
    • a cyclical pattern of occurrence has been noted for GPA but not MPA
  • approximately 85% to 90% of patients with GPA, 70% of those with MPA and approximately 30% to 40% of patients with EGPA are ANCA-positive (2)
  • there are geographical differences in the incidence of AAV
    • for example a comparative study in Europe using the same classification criteria in three populations (Lugo, North-western Spain; Norwich, UK; and Tromsø, Northern Norway) reported that GPA was more common in Norway than in Spain, while MPA had the reverse distribution
    • in South-East Asian populations (Japan, China) myeloperoxidase (MPO)-AAV is relatively more common than vasculitis associated with antibodies to PR3 (PR3-AAV), although the overall incidence of AAV is similar

References:

  1. ARC Autumn 2012. Topical Reviews - ANCA-associated vasculitis; 1:1-12.
  2. Bala MM et al. Anti-cytokine targeted therapies for ANCA-associated vasculitis. Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No.: CD008333.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.